-
Je něco špatně v tomto záznamu ?
Celiac disease pipeline: An Examination of new treatment options currently under investigation
Eric P. Borrelli Pharm D
Jazyk angličtina Země Spojené státy americké
- MeSH
- celiakie * farmakoterapie MeSH
- klinická studie jako téma MeSH
- lidé MeSH
- vyvíjení léků MeSH
- Check Tag
- lidé MeSH
Celiac disease is a chronic gastrointestinal autoimmune disease that occurs in approximately 0.5-1% of the U.S. population. At this point in time there is no cure nor therapeutic option available for patients with CD. The only treatment option is a 100% strict adherence to a gluten free diet. However, even complete adherence may not be enough as some foods might contain cross contaminated gluten. The purpose of this study was to analyze and describe different therapy options currently being investigated for potential use in patients with CD. An analysis of ClinicalTrials.gov was performed with the search term “Celiac Disease”. The search returned 192 results, however only 8 were pharmacologic treatment options. The pharmacologic therapies located were TIMP-GLIA, ALV003, AMG714, pancrelipase, Nexvax2, RO5459072, Hu-Mik Beta-1, and Necator americanus (Na). With the nonexistent treatment options currently available, further research needs to be completed to create new therapeutic options for patients with CD with the goal of ultimately curing patients.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18028279
- 003
- CZ-PrNML
- 005
- 20201021112622.0
- 007
- ta
- 008
- 180814s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.12691/ijcd-6-2-8 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Borrelli, Eric P. $u University of Rhode Island College of Pharmacy, Kingston, Rhode Island
- 245 10
- $a Celiac disease pipeline: An Examination of new treatment options currently under investigation / $c Eric P. Borrelli Pharm D
- 504 __
- $a Literatura
- 520 9_
- $a Celiac disease is a chronic gastrointestinal autoimmune disease that occurs in approximately 0.5-1% of the U.S. population. At this point in time there is no cure nor therapeutic option available for patients with CD. The only treatment option is a 100% strict adherence to a gluten free diet. However, even complete adherence may not be enough as some foods might contain cross contaminated gluten. The purpose of this study was to analyze and describe different therapy options currently being investigated for potential use in patients with CD. An analysis of ClinicalTrials.gov was performed with the search term “Celiac Disease”. The search returned 192 results, however only 8 were pharmacologic treatment options. The pharmacologic therapies located were TIMP-GLIA, ALV003, AMG714, pancrelipase, Nexvax2, RO5459072, Hu-Mik Beta-1, and Necator americanus (Na). With the nonexistent treatment options currently available, further research needs to be completed to create new therapeutic options for patients with CD with the goal of ultimately curing patients.
- 650 12
- $a celiakie $x farmakoterapie $7 D002446
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a klinická studie jako téma $7 D000068456
- 650 _2
- $a vyvíjení léků $7 D000076722
- 773 0_
- $t International journal of celiac disease $x 2334-3427 $g Roč. 6, č. 2 (2018), s. 33-36 $w MED00186448
- 856 41
- $u http://www.sciepub.com/journal/index.aspx?id=ijcd $y domovská stránka časopisu
- 910 __
- $a ABA008 $b B 2748 $c 280 $y p $z 0
- 990 __
- $a 20180814135551 $b ABA008
- 991 __
- $a 20201021112619 $b ABA008
- 999 __
- $a ok $b bmc $g 1325913 $s 1025234
- BAS __
- $a 3
- BMC __
- $a 2018 $b 6 $c 2 $d 33-36 $i 2334-3427 $m International journal of celiac disease $x MED00186448
- LZP __
- $c NLK192 $d 20201010 $a NLK 2018-15/dk
